Holly Yellson

PHD Doctor of Philosophy,  The Johns Hopkins Hospital 

Location: United States

Consulting Services

Data Science-Bioinformatics Legal Support Sales and Marketing

Areas Of Interest

Orexin Receptor Type 1 Labyrinths, Vestibular Reductase Defensive Practice COS Cells PC5B Preprotein Convertase Caucasian Race Chromosomes, Human, 21-22 and Y CYP3A7 Inhibitors Cyclospora Aspartic Acid, Calcium Salt Synovial Plica Syndrome Relations, Community-Institutional Fructose Intolerance, Hereditary Group, Oceanic Ancestry Systems, Two-Partner Secretion Arteries, Gastroepiploic Dental Soldering Quinidex TGF beta3 Mucopect, Dampo Lithocholyltaurine LM 2717 GABA A Receptor delta Subunit Shoulder-Girdle Neuropathies Positrons Region Trauma, Frontal Harpacticoidas Blastocyst Culture Techniques Patient Ombudsmen Molerats Metandren Tetrahymena thermophila Complete Hydatidiform Moles Device, Foot Orthotic Cyclin B2 BBK 8 Smokings, Giving Up

Professional Narrative

Dr. Holly Yellson was born in DuBois, Pennsylvania and is a graduate of Villanova University. He obtained his medical degree at Thomas Jefferson University in Philadelphia. His residency was at Thomas Jefferson and its affiliated Wills Eye Hospital, and he completed his training with fellowships at the University of Connecticut incataract andcorneal surgery.

Dr. Yellson has thirty years’ experience in ophthalmic surgery,withspecialinterestin cataract surgery,corneal transplantation,andlaserrefractiveprocedures.Heisa founding member of Precision LASIK Group, Chief of Ophthalmology at The Hospital ofCentral Connecticut,andco-medical director of the Connecticut eye bank.


Employment

Senior Director, Harvard Med 2013
Medical Writer, Mayo Clinic 2010

Education

Master of Science in physician assistant, Yale School of Medicine 1989
Master of Science in physician assistant, Perelman School of Medicine 2015

Referees


Publications

Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020 Oct;19(10):673-694. doi: 10.1038/s41573-020-0075-7. Epub 2020 Aug 11. PMID: 32782413; PMCID: PMC7419031.

Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020 Oct;19(10):673-694. doi: 10.1038/s41573-020-0075-7. Epub 2020 Aug 11. PMID: 32782413; PMCID: PMC7419031.

Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078-1094. doi: 10.1038/s41578-021-00358-0. Epub 2021 Aug 10. PMID: 34394960; PMCID: PMC8353930.

Oberli MA, Reichmuth AM, Dorkin JR, Mitchell MJ, Fenton OS, Jaklenec A, Anderson DG, Langer R, Blankschtein D. Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. Nano Lett. 2017 Mar 8;17(3):1326-1335. doi: 10.1021/acs.nanolett.6b03329. Epub 2016 Dec 5. PMID: 28273716; PMCID: PMC5523404.


Grants,Awards and Certifications

Grants :

No Grants Mentioned !!

Awards & Prizes :


Languages

Language Proficiency :

Translation Services :